Navigation Links
SNM seeks novel approaches to molecular imaging to showcase at annual meeting
Date:9/21/2007

ore, Md.

Were looking for the brightest researchers and cutting-edge science that show us the possibilities of molecular imaging with personalized medicine, explained Frederic H. Fahey, chair of the societys Scientific Program Committee and the director of nuclear medicine/PET physics at Childrens Hospital Boston and associate professor of radiology at Harvard Medical School. Fahey encourages researchers to submit pre-clinical in vitro or in vivo and clinical studies.

The new scientific track will encompass cardiovascular, neuroscience, oncology, general specialties, instrumentation and data analysis topics and non-radioactive molecular imaging agents. The societys online abstract submitter opens Oct. 25 and closes Jan. 10, 2008. The submission deadline for technologist students is Feb. 7, 2008.

If you have any questions, please contact Heather Jacene, vice chair of the new track, via e-mail at hjacene1@jhmi.edu. For more information about SNM abstract tracks, categories and awards, go online to http://www.snm.org/abstracts.


'/>"/>

Contact: Maryann Verrillo
mverrillo@snm.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Consumer group seeks Sibutramine ban
2. Gujarat Seeks To Scale Down Infant Mortality Rate
3. Europe Seeks Indian Expertise
4. Book Seeks To Rehabilitate Soldiers
5. Government Seeks To Wipe Out Prostitution
6. Multiple Sclerosis Patient Seeks Help of Stem Cells
7. Pro-reservation body seeks removal of AIIMS Director
8. AIIMS Doctors Seeks Ramadoss Intervention For Venugopal’s Remova
9. Human Chain Seeks AIIMS Status For Tiruchi Medical College
10. Harney Seeks Approval for New Medical Practitioners Bill
11. Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release 3A August 3 2009 51439 1Varian Medical Systems Management to Present at the Piper Jaffray Cancer Summit 51436 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 1Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 2Medical Imaging Modality Vendors Should Focus on Innovation and Alliances with Market Leaders Advises Frost 26 Sullivan 51431 3